Sentrian, the World's First Remote Patient Intelligence Company, Launches to Eliminate Preventable Hospitalization

Company raises $12 Million in financing led by Reed Elsevier Ventures, Frost Data Capital and TELUS Ventures

Leadership team includes former Chief Medical Scientist of IBM Research

Nov 10, 2014, 08:03 ET from Sentrian

SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Sentrian™ (formally Jointly Health), the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, formally launched today at Singularity University's Exponential Medicine Conference.

"Millions of unnecessary hospitalizations that endanger patients and cost tens of billions of dollars every year could be avoided if we could spot deterioration in patients' health earlier using remote patient monitoring analytics," said Dean Sawyer, Co-Founder and CEO of Sentrian, headquartered in Aliso Viejo, California. "Our platform leverages the exponential growth in biosensors and machine-learning and is intended to detect the subtle signs that warn of an impending problem before the patient becomes acute and requires hospitalization."   

Peter Diamandis, Founder and Chairman of the X Prize Foundation, Co-Founder of Singularity University, and named one of  "The World's 50 Greatest Leaders" by Fortune magazine, said, "The idea for Sentrian was born out of one of the first Singularity University Executive Programs and is a great example of how small teams leveraging accelerating technologies can make a massive impact. Sentrian is very well positioned to impact the problem of chronic disease, which is crippling economies and causing an unquantifiable amount of human suffering."

$12 million from multiple investors
Sentrian has raised $12 million in financing including $4 million in seed funding and $8 million in a recent Series A round led by Reed Elsevier Ventures, Frost Data Capital and TELUS Ventures.

"As healthcare moves from volume to value-based reimbursement, tackling preventable hospital admissions becomes an imperative," said Kevin Brown, General Partner of Reed Elsevier Ventures.  "Sentrian has assembled a dream team of entrepreneurs, technologists and physicians and has developed the only analytics platform we've seen capable of taking advantage of multivariate remote patient monitoring sensor data at scale. I am thrilled to be joining the Sentrian team as an investor and board member."

Jack Kreindler, MD, Sentrian's Founder and Chief Medical Officer, said, "There is an extraordinary opportunity and need today to apply exponentially accelerating advances in biosensor technology and human-augmented machine learning to finally make remote patient management an affordable and effective reality for patients, payers and providers alike. Sentrian is turning the unprecedented stream of data from remote sensors into foresight and intelligence, bridging the chasm between patients at home and providers in clinics and hospitals – transforming the very way medicine manages disease, and helping to solve a grand challenge in healthcare." 

Former IBM Research medical executive joins leadership team
In addition to Sawyer, who is a former senior executive of Allscripts and Physicians Interactive, Sentrian's leadership team includes Chief Medical Scientist Martin Kohn, MD, MS, FACEP, a world-renowned expert in healthcare population analytics and the role of expert systems in the clinical decision process. Dr. Kohn was previously the Chief Medical Scientist for Care Delivery Systems in IBM Research, where he led IBM's support for the transformation of healthcare, including the use of the Watson supercomputer in healthcare.

Sentrian's platform is currently being tested by large health insurance plans in controlled studies involving thousands of patients.  The company expects to announce the results of those studies in 2015.

About Reed Elsevier Ventures
Reed Elsevier Group plc is a world leading provider of professional information solutions. The group employs approximately 28,000 people of whom half are in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV; the combined market capitalisation of the two parent companies is approximately £20bn/€25bn. Its shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

About Sentrian
Sentrian™, the first Remote Patient Intelligence™ company, aspires to eliminate all preventable hospitalization by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute. Sentrian's value proposition to healthcare organizations is to provide a cloud-based remote patient monitoring and analytics platform intended to dramatically reduce preventable hospital admissions, increase the efficiency and effectiveness of care teams and improve quality metrics such as HEDIS and Star ratings. The Sentrian platform is designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Find us at, on Twitter and LinkedIn.

Joy DiNaro
Amendola Communications for Sentrian

Logo -

SOURCE Sentrian